A single dose of apixaban for the prevention of thrombotic events in the context of long-distance flights (DANCE FLIGHT)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515630-33-00

Acronym

2023-01-1200-01

Enrollment

27698

Registered

2024-11-11

Start date

Unknown

Completion date

2025-11-12

Last updated

2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic leg vein thrombosis

Brief summary

The occurrence of clinically relevant leg vein thrombosis.

Detailed description

Occurrence of clinically relevant and non-relevant leg vein thromboses, Occurrence of any bleeding (BARC ≥ 1)

Interventions

DRUGEliquis 2.5 mg film-coated tablets

DRUGHard-gelantine capsule filled with Mannitol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The occurrence of clinically relevant leg vein thrombosis.	—

Secondary

Measure	Time frame
Occurrence of clinically relevant and non-relevant leg vein thromboses, Occurrence of any bleeding (BARC ≥ 1)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026